Keytruda and Systemic sclerosis (scleroderma) - a phase IV clinical study of FDA data

Summary:

Systemic sclerosis (scleroderma) is reported as a side effect among people who take Keytruda (pembrolizumab), especially for people who are male, 60+ old, have been taking the drug for 1 - 2 years also take Lenvima, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Systemic sclerosis (scleroderma) when taking Keytruda. It is created by eHealthMe based on reports of 57,304 people who have side effects when taking Keytruda from the FDA, and is updated regularly.

What is Keytruda?

Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,404 Keytruda users. Check the latest studies of Keytruda.

What is Systemic sclerosis (scleroderma)?

Systemic sclerosis (scleroderma) (an autoimmune or connective tissue disease. it is characterized by thickening of the skin) is found to be associated with 495 drugs and 857 conditions by eHealthMe. Check the latest studies of Systemic sclerosis (scleroderma).

On Jul, 16, 2026

57,304 people reported to have side effects when taking Keytruda.
Among them, 18 people (0.03%) have Systemic sclerosis (scleroderma).

Could Keytruda cause Systemic sclerosis (scleroderma)?

Among these 18 people:

How long have people been on Keytruda when they have Systemic sclerosis (scleroderma)? *

What is the gender of people who have Systemic sclerosis (scleroderma) when taking Keytruda? *

female: 29.41 %
male: 70.59 %

What is the age of people who have Systemic sclerosis (scleroderma) when taking Keytruda? *

What are other drugs people take besides Keytruda? *

What are other side effects people have besides Systemic sclerosis (scleroderma)? *

Hepatitis (inflammation of the liver): 2 people, 11.11%
Rashes (redness): 2 people, 11.11%
Thyroiditis (inflammation of thyroid gland): 1 person, 5.56%
Myositis (inflammation of the muscles): 1 person, 5.56%
Encephalitis (inflammation of the brain): 1 person, 5.56%
High Blood Pressure: 1 person, 5.56%
Hyponatremia (abnormally low level of sodium in the blood; associated with dehydration): 1 person, 5.56%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 5.56%
Interstitial Nephritis (inflammation of the kidney): 1 person, 5.56%
Neuropathy Peripheral (surface nerve damage): 1 person, 5.56%

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 4 people, 22.22%
Malignant Melanoma (skin cancer rises from melancytes): 3 people, 16.67%
Non-Small Cell Lung Cancer Stage Iv: 2 people, 11.11%
Lung Neoplasm Malignant (cancer tumour of lung): 2 people, 11.11%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 11.11%
Rashes (redness): 1 person, 5.56%
Pain: 1 person, 5.56%
Malignant Melanoma Stage Iv (the cancer has spread to other places in the body, such as the lung, liver, brain, bone, soft tissue, or gastrointestinal (gi) tract. cancer may have spread to places in the skin far away from where it first started): 1 person, 5.56%
Malignant Melanoma Stage Iii (cancer has spread to one or more lymph nodes): 1 person, 5.56%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Keytruda and have Systemic sclerosis (scleroderma)?

- Check whether Systemic sclerosis (scleroderma) is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Keytruda:

Keytruda (57,404 reports)

Browse all side effects of Keytruda:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Systemic sclerosis (scleroderma):

Systemic sclerosis (scleroderma) (495 drugs)

Browse all the conditions that are associated with Systemic sclerosis (scleroderma):

Systemic sclerosis (scleroderma) (857 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pembrolizumab (the active ingredients of Keytruda) and Keytruda (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.